Brain-gut peptide action has been best studied in certain target cells of the gastrointestinal tract such as isolated pancreatic acini. Cholecystokinin (CCK) activation of pancreatic digestive enzyme secretion is initiated by specific receptors present in the basolateral membrane of the acinar cell. These receptors are highly selective for CCK and readily discriminate it from the homologous peptide, gastrin. Studies covalently crosslinking125I-CCK to its receptor have revealed a binding glycoprotein subunit of Mr= 76,000 attached by a disulfide bridge to a Mr=40,000 nonbinding subunit. Receptor occupancy leads to phosphotidylinositide breakdown and Ca2+ mobilization. Recent studies with the fluorescent chelate probe Quin-2 have shown that CCK increases cytosolic Ca2+ from a basal level of 100 nM to 500-1000 nM. The effects of Ca2+, and diacylglycerol produced by the breakdown of phosphoinositides, are believed mediated by activation of a group of protein kinases and phosphatases.
INTRODUCTION
The brain-gut peptides comprise a diverse group of peptides and polypeptides which are present in both the brain and the gastrointestinal tract and have a biologic effect in at least one location.
In the brain they are believed to function as neuroregulators or neuromodulators while in the periphery they may function as hormones, paracrine regulators or neurotransmitters.
In most cases the molecules have been isolated, sequenced and chemically synthesized, although some have been defined in the brain solely on the basis of immunoreactivity.
In concert with other regulatory peptides the action of brain-gut peptides is believed to be initiated by binding to specific membrane receptors. This may lead directly to activation of membrane ion channels as is the case for traditional neurotransmitters but in most cases leads to generation of intracellular messengers such as cyclic AMP, Ca" or diacylglycerol. Brain-gut peptide action has been best studied in certain target cells of the gastrointestinal tract. The isolated pancreatic acini is a well studied system as acini can easily be prepared from mice, rat and guinea pig pancreas by collagenous digestion (Williams, Korc and Dormer, 1978) . This results in a homogenous suspension which responds with a number of quantifiable biologic effects such as amylase secretion in response to a number of braingut peptides (Williams, 1984) . Of these peptides, cholecystokinin (CCK), bombesin, and substance P act via phosphotidylinositide turnover and an increase in cytoplasmic Ca'. By contrast vasoactive intestinal polypeptide (VIP), secretin, and peptide histidine-isoleucine (PHI) act via cyclic AMP. This review will focus on receptors and actions of CCK on the pancreas and compare these to their counterparts in brain. Mention will also be made of VIP and its actions.
PANCREATIC CCK RECEPTORS
Pancreatic digestive enzyme secretion in response to CCK is initiated by binding to specific receptors located on the basolateral membrane of the acinar cell (Williams et. al., 1982) . These receptors have been characterized using biologically active CCK-33 or CCK-8 properties is also present on gallbladder membranes (Steigerwalt, Goldfine and Williams, 1984) . CCK's action on pancreatic acini is blocked by a number of inhibitors which competitively block CCK binding to its receptor. Of these dibutyryl cyclic GMP and CCK26_32
(CCK-8 without its carboxyl terminal phenylalamine) are the most potent with proglumide and benzotrypt being much weaker (Gardner and Jensen, 1984) . The acinar CCK receptor has been characterized as to size and subunit composition by covalently crosslinking 125 I-CCK to its receptor using bifunctional crosslinkers or by means of UV light ( Fig. 2 , left panel). When disulfide bonds are reduced with dithiothreitol, CCK (Mr=4,000) is bound to a Mr=76,000 protein. In the absence of reducing agent the main labeled species is Mr=120,000. This labeled Mr=120,000 protein can be exised, reduced and converted to the Mr= 80,000 species Williams, 1983: 1984) . Therefore the pancreatic CCK receptor is believed to consist of a 76,000 dalton binding subunit coupled to a 40,000 dalton non-binding subunit. While the function of the non-binding subunit is unknown it is tempting to speculate it could be involved in signal tranduction. CCK acting via Ca2+ and phosphotidylinositide breakdown activates a number of protein kinases and phosphatases in pancreatic acini. At present two general classes of Ca2+-dependent kinases have been described in pancreatic acinar cells, calmodulin dependent , calcium activated kinase and calcium-phosphotidylserine dependent, diacylglycerol activated kinase (Burnham and Williams, 1984a ). The latter is clearly similar to protein kinase C described in a number of tissues (Nishizuka, 1984) . It is not clear how many specific calmodulin dependent kinases are present in acinar cells; in other cells multiple kinases have been described with distinct substrate specificities. One specific kinase capable of phosphorylating ribosomal protein S6 has been purified from rat pancreas (Gorelick et. al., 1983) . In addition to these kinases, Ca2+ activated protein phosphatase activity is also present in acinar cells (Burnham and Williams, 1984b ). These Ca2+ activated kinases and phosphatases are believed to mediate the changes in protein phosphorylation observed when pancreatic acini are stimulated with CCK. We have described five proteins in acini whose phosphorylation increased or decreased in response to CCK (Burnham and Williams, 1982 (Williams, 1984) . A schematic diagram summarizing how CCK and these other brain-gut peptides act on acinar cells to initiate pancreatic enzyme secretion is shown in Figure 3 .
CCK RECEPTORS AND ACTIONS IN BRAIN
Considerably less is known about the actions and mechanism of action of CCK in brain than in pancreas. While CCK has been described to alter the firing rates of some neurons in the CNS, it is not clear whether CCK functions as a neurotransmitter or in a more general role. To date there are no reports of CCK-induced phosphotidylinositide turnover, altered
Ca2+ fluxes or protein phosphorylation in brain slices or synaptosomes. In the peripheral nervous system CCK does act on gut neurons in the intestinal myenteric plexus to release acetylcholine.
Considerably more effort and success has resulted from studies of brain CCK receptors (Williams et. al., 1985) . Binding studies with 125 I-CCK have shown specific, reversible and saturable binding to brain membranes. These receptors are distributed throughout the brain but are most highly concentrated in the cerebral cortex, olfactory bulb and caudate with a general rostral to caudal gradient. Autoradiographic studies have shown that CCK binding is not diffuse but localized in specific laminae and nuclei (Zarbin et. al., 1983) . Binding studies have shown both similarities and differences between brain and peripheral CCK receptors. Brain membrane receptors show an acid pH optimum, a requirement for Mg2+ and a similar Kd of about 1 nM to receptors on similarly prepared pancreatic membranes. A major difference, however, is that most analogs of CCK and gastrin can compete with 125I -CCK for binding to the brain CCK receptor (Fig . 1) . In rat and mouse brain membranes CCK-8 was slightly more potent than CCK-33 whereas gastrin, desulfated CCK-8 and CCK-4 were slightly less potent. Thus all the molecular forms of CCK present in brain should be able to interact with the CCK receptor. Recently we have shown that CCK-4 represents the minimal CCK sequence for high affinity CCK interaction with brain receptors as CCK-3 is 1000 fold weaker (Steigerwalt and Williams, 1984) . Another difference between mammalian brain and pancreas CCK receptors is in their interaction with antagonists. Specifically, dibutyryl cyclic GMP, a selective inhibitor of the pancreatic CCK receptor, is twenty fold weaker as an inhibitor of brain CCK binding and no more potent than GMP or cyclic GMP (Saito et. al., 1981) . Brain CCK receptors also appear structurally distinct from pancreatic receptors. Covalent crosslinking techniques previously described for pancreatic receptors when applied to brain membranes show a major protein band of about Mr= 55,000 in the presence or absence of reducing agent (Fig. 2, right panel) . The appearance of this band can be blocked by incubation with excess CCK-8 or CCK-4 prior to crosslinking. This is in contrast to pancreas where CCK-8 but not CCK-4 blocks the appearance of the labeled bands. Thus we believe that the brain CCK receptor is structurally distinct and consists of a single binding subunit. This structural difference may underly some of the differences in agonist and antagonist receptor specificity. While we assumed originally that the pancreas would be a model for understanding CCK action in the brain it now looks like two different systems may have emerged. That evolutionary diversity has occurred is indicated by our recent finding that in amphibia and lower vertebrates the CCK receptors are similar in brain and pancreas (Williams et. al., 1985) .
OTHER PEPTIDES IN BRAIN
Similar to our current state of knowledge as to CCK, the action of other brain-gut peptides is considerably less advanced in brain than in the gut. Specific brain receptors have been described for a number of peptides including bombesin, substance P, somatostatin, calcitonin, VIP and secretin. While the mechanism of most of these peptides is not well understood, VIP and secretin appear to act via cyclic AMP as they do in the gut. Thus VIP activated adenylate cyclase is present in synaptosomal membranes (Robberecht et. al., 1978) and VIP increases cyclic AMP accumulation in cultured brain cells (Van Calker, Muller and Hamprecht, 1980) . In the superior cervical ganglion, VIP and secretin activate tyrosine-3-monoxygenase (Ip et. al., 1982) . Such actions could underly a neuromodulator role for this class of brain-gut peptides.
